What is Important to Patients in Oncology Clinical Studies?
November 17, 2021
What is important to patients in oncology clinical studies? Clario’s eCOA Science Team experts Kelly Dumais, Ph.D., and Stephen Raymond, Ph.D., explore the role of ePRO and the right endpoints in reducing patient burden during oncology studies and cancer drug clinical trials. Read the full article below.
About Clario
Clario delivers the leading endpoint technology solutions for oncology studies and cancer drug clinical trials. Through experience gained from over 19,000 clinical trials delivered in support of 870 regulatory approvals, Clario fuses scientific expertise and global scale into the broadest endpoint technology platform to enable pharmaceutical, biotech and medical device partners to transform lives. Clario has mastered the ability to generate rich evidence across all trial models: decentralized, hybrid and site-based clinical trials. With 30 facilities in nine countries across North America, Europe and Asia Pacific, Clario’s global team of science, technology and operational experts has been delivering the richest clinical evidence for oncology studies and cancer drug clinical trials for nearly 50 years.
For more information, go to Clario.com or follow us on LinkedIn and Twitter.